Tech Company Financing Transactions
Ultromics Funding Round
Ultromics, based in Oxford, raised investment capital from American Heart Association.
Transaction Overview
Company Name
Announced On
12/17/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The funding accelerates Ultromics' mission to make early identification of heart failure a standard part of cardiac care, expanding access to its FDA-cleared AI platform already used in leading U.S. hospitals and reimbursed across public and private payers.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
4630 Kingsgate, Cascade Way, Oxford Business Park South
Oxford, OX4 2SU
UK
Oxford, OX4 2SU
UK
Phone
Website
Email Address
Overview
At Ultromics, we are committed to improving outcomes for patients with heart failure, which affects 64 million people worldwide.[1?] Through the development of? AI-based solutions we help diagnose specific phenotypes of heart failure, beginning with HFpEF, so that patients can receive life-saving treatments earlier. Ultromics brings the power of artificial intelligence into your echocardiography workflow using a state-of-the-art platform that supports early heart failure diagnosis.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/17/2025: Roamless venture capital transaction
Next: 12/17/2025: Mythic venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








